4.5 Article

NCCN Guidelines® Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines

Journal

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2018.0026

Keywords

-

Categories

Funding

  1. AstraZeneca
  2. Celldex Therapeutics
  3. Celgene Corporation
  4. Genentech
  5. Jazz Pharmaceuticals, Inc.
  6. Novartis Pharmaceuticals Corporation
  7. Seattle Genetics, Inc
  8. AbbVie
  9. Merck Co., Inc.
  10. NOVOCURE

Ask authors/readers for more resources

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the H&N, and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding evaluation and treatment of nasopharyngeal carcinoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available